---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-047977"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2022-04-21T23:59:59+00:00"
generated_at: "2026-06-26T05:51:57.764224+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Merck ends exclusion of upfront/milestone payments and pre-approval asset charges from non-GAAP results

## Summary
- Merck will no longer exclude upfront/milestone payments and pre-approval asset acquisition charges from non-GAAP results, effective Q1 2022.
- Recast FY2021 non-GAAP EPS from continuing ops is $5.37, down from previously reported $6.02; FY2020 revised to $2.97 from $4.53.
- Change aligns with SEC staff views; does not affect Q1 2021 or Q1 2022 non-GAAP results.
- Revised non-GAAP R&D expense for full-year 2021 is $11,738M vs previously reported $10,077M (increase of $1,661M).
- The recast 2021 annual net income attributable to Merck is $13,623M vs previously $15,282M.

## SEC filing metadata
- accession: 0001104659-22-047977
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2022-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465922047977/0001104659-22-047977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465922047977/tm2212593d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-047977
- JSON: https://secwatch.observer/filing/0001104659-22-047977.json
- Plain text: https://secwatch.observer/filing/0001104659-22-047977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.